European biotechnology company Valneva SE ("Valneva") and UK company BliNK Therapeutics Ltd ("BliNK Therapeutics") announced today the closing of the transaction creating BliNK Biomedical SAS, a private company specialised in the discovery of innovative monoclonal antibodies.
The new company is owned by Valneva, Kurma Biofund I (founding investor of BliNK Therapeutics), funds managed by Idinvest Partners, Cancer Research Technology (CRT) and BliNK Therapeutics’ founders.
BliNK Therapeutics’ technology has been developed by Facundo Batista, Head of the Lymphocyte Interaction Laboratory at Cancer Research UK's London Research Institute.
Amplia Therapeutics presents mature data from its ACCENT Phase 2a trial in metastatic pancreatic cancer at the AACR Annual Meeting as part of a mini-symposium entitled Advances in Precision Oncology being held in San Diego.
Cancer Research Technology Limited (CRT) and The Institute of Cancer Research announce that Vernalis plc has licensed exclusive worldwide rights to an anti-cancer Hsp90 inhibitor programme.
Investors in residence, Genghis Lloyd Harris and Jonathan Tobin discuss the current market and how their roles fit into it.
